Praxis Precision Medicines, Inc.

PRAX

$355.15

-0.66%

2026-09-03 16:00:00 EDT-$2.35

Healthcare

Biotechnology

NASDAQ

Active Trading

Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system ...

Financial Highlights of PRAX

Profitability trend

Latest / TTM · 6 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-27.42x

n/a

Debt / Equity

0.00

n/a

Current Ratio

15.73

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Financial highlights

Latest / TTM · 6 periods

Snapshot

Latest / TTM: 2026-09-04

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-27.42x

Debt / Equity

0.00

Profitability

Profitability table

Metric	2021	2022	2023	2024	2025	2026
Gross MarginGross profit as a percentage of revenue.	0.0%	0.0%	-3445.8%	-1682.0%	0.0%	—
Operating MarginOperating income as a percentage of revenue.	0.0%	0.0%	-5164.4%	-2340.3%	0.0%	—
Net MarginNet income as a percentage of revenue.	0.0%	0.0%	-5037.9%	-2137.5%	0.0%	—
EBITDA MarginEBITDA divided by revenue.	0.0%	0.0%	-5020.2%	-2133.3%	0.0%	—
Pre-tax MarginPre-tax profit as a percentage of revenue.	0.0%	0.0%	-5037.9%	-2137.5%	0.0%	—

Liquidity & leverage

Liquidity & leverage table

Metric	2021	2022	2023	2024	2025	2026
Current RatioCurrent assets divided by current liabilities.	7.48	3.23	5.39	10.77	10.22	—
Quick RatioLiquid assets divided by current liabilities.	7.48	3.23	5.39	10.77	10.22	—
Cash RatioCash and equivalents divided by current liabilities.	3.61	1.79	5.16	5.74	5.98	—
Debt / AssetsDebt as a share of total assets.	1.5%	3.0%	2.8%	0.3%	0.0%	—
Debt / EquityDebt compared with shareholder equity.	0.02	0.05	0.04	0.00	0.00	—

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	2026
Receivables TurnoverHow often receivables are collected in a year.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Inventory TurnoverHow often inventory is sold in a year.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Payables TurnoverHow often payables are paid in a year.	0.00x	10.53x	14.92x	12.17x	0.01x	—
Asset TurnoverRevenue generated per dollar of assets.	0.00x	0.00x	0.03x	0.02x	0.00x	—
Working Capital TurnoverRevenue generated per dollar of working capital.	0.00x	0.00x	0.03x	0.04x	0.00x	—

Valuation ratios

Valuation ratios table

Metric	2021	2022	2023	2024	2025	2026
P/E RatioPrice paid for each dollar of earnings.	-5.01x	-0.51x	-1.19x	-7.54x	-21.86x	—
P/B RatioPrice paid for each dollar of book value.	3.33x	1.44x	2.11x	3.09x	7.55x	—
P/S RatioPrice paid for each dollar of sales.	0.00x	0.00x	60.04x	161.13x	0.00x	—
P/FCF RatioPrice paid for each dollar of free cash flow.	-6.66x	-0.59x	-1.32x	-10.46x	-26.63x	—
Dividend YieldAnnual dividend divided by current share price.	0.0%	0.0%	0.0%	0.0%	0.0%	—

Supply Chain of PRAX

RELATIONS

Upstream

WuXi AppTec (STA Pharmaceutical)SHA:603259Thermo Fisher Scientific Inc. (Patheon)NYSE:TMO ICON plcNASDAQ:ICLRParexel International CorporationCharles River Laboratories International, Inc.NYSE:CRLEurofins Scientific SE (Eurofins Lancaster Laboratories)ENXTPA:ERFSigma-Aldrich (Merck KGaA)XETRA:MRKSAFC (Sigma-Aldrich Fine Chemicals)XETRA:MRKBio-Rad Laboratories, Inc.NYSE:BIO

Downstream

Novartis AGNYSE:NVSUndisclosed Pharmaceutical Partner(s)McKesson Corporation (US Oncology / Specialty Health)NYSE:MCK AmerisourceBergen Corporation (Cencora)NYSE:CORClinical Trial Sites (Hospitals & Academic Institutions)

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer